






































hLeukemia Research 37 (2013) 877– 882
Contents lists available at SciVerse ScienceDirect
Leukemia  Research
j o ur nal ho me page: www.elsev ier .com/ locate / leukres
zacitidine  results  in  comparable  outcome  in  newly  diagnosed  AML  patients
ith  more  or  less  than  30%  bone  marrow  blasts
.H.  van  der  Helma,  N.J.G.M.  Veegera, M.  van  Marwijk  Kooyb, A.  Beekerc, O.  de  Weerdtd,
. de  Groote,  C.  Alhanf,  M.  Hoogendoorng,  L.  Laterveerh,  A.A.  van  de  Loosdrecht f,
.  Koedami,  E.  Vellengaa, G.  Hulsa,∗
Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands
Department of Internal Medicine, Isala Klinieken, Zwolle, The Netherlands
Department of Internal Medicine, Spaarne Ziekenhuis, Hoofddorp, The Netherlands
Department of Internal Medicine, Sint Antonius Hospital, Nieuwegein, The Netherlands
Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands
Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
Department of Hematology, Medical Center Leeuwarden, Leeuwarden, The Netherlands
Department of Internal Medicine, Diaconessenhuis, Meppel, The Netherlands
Celgene BV, Utrecht, The Netherlands
a  r  t  i  c  l e  i  n  f  o
rticle history:
eceived 14 January 2013
eceived in revised form 25 March 2013
ccepted 30 March 2013
vailable online 28 April 2013
a  b  s  t  r  a  c  t
The  efﬁcacy  of azacitidine  has been  demonstrated  in acute  myeloid  leukemia  (AML)  patients  with  20–30%
bone  marrow  (BM)  blasts,  but  limited  data  is available  on  patients  with ≥30% blasts.  We  analyzed  55 newly
diagnosed  AML patients,  treated  with  azacitidine.  The  overall  response  rate  was  42%.  Median  overall
survival  (OS)  was  12.3 months.  We  conﬁrmed  poor-risk  cytogenetics,  therapy-related  AML,  performance




one marrow blast count
redictors
percentage,  however,  had  no impact  on  OS  (P =  0.55).
In conclusion,  administration  of  azacitidine  is  effective  in  AML  patients  with  20–30%  and  >30%  BM
blasts.
© 2013 Elsevier Ltd. All rights reserved.. Introduction
Acute myeloid leukemia (AML) is a heterogeneous clonal
isorder of hematopoietic progenitor cells with different molec-
lar genetic abnormalities, clinical characteristics, and variable
utcomes with currently available treatment [1,2]. AML  is
ost common in the elderly with a median age at pre-
entation of approximately 70 years [2]. Older AML  patients
enerally have a limited beneﬁt with currently available
reatment due to a combination of poor chemotherapeutic
olerance and inherent disease resistance [3–10]. Neverthe-
ess, several studies on intensive and non-intensive treatment
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ttp://dx.doi.org/10.1016/j.leukres.2013.03.022types suggest that older AML  patients beneﬁt from treatment
[11,12].
Recently, azacitidine has become available for (older) AML
patients with 20–30% bone marrow (BM) blasts. A phase 3 study
demonstrated that azacitidine signiﬁcantly improved OS  in higher-
risk MDS  patients compared to best supportive care and low-dose
cytarabine [13]. A post hoc analysis of this study showed improved
OS in the subgroup of AML  patients with 20–30% blasts treated
with azacitidine compared with best supportive care [14]. The
efﬁcacy of azacitidine in previously untreated AML  patients has
been conﬁrmed in a retrospective analysis of an Italian compas-
sionate program and in a small German prospective multicenter
study [15,16]. However, until now no comparison of treatment
outcome has been made between AML  patients with 20–30% BM
blasts, for whom azacitidine is generally available, and patients
with 30% or more BM blasts, who  can only be treated off-
label. Therefore, we analyzed the treatment results of 55 newly
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. Patients and methods
.1. Patients and data collection
After FDA approval of azacitidine in the US and before EMA  approval in the EU,
 compassionate named patient program (NPP) was initiated in the Netherlands for
DS, CMML, and AML  patients with 20–30% blasts. The results of this Dutch NPP
ave been reported [17]. In the present retrospective study, the NPP was  extended
nd an analysis was made of 55 consecutive newly diagnosed AML patients (with
0–30% and >30% BM blasts) who have been treated upfront with azacitidine. Data
f this extended compassionate NPP has been collected between August 2010 and
arch 2012 after informed consent in accordance with the Declaration of Helsinki
y studying health records. Diagnoses were made using World Health Organization
WHO)-2008 criteria [18]. Cytogenetic risk could be determined in 52 of 55 patients
ccording to the reﬁned cytogenetic classiﬁcation of the Medical Research Council
19]. The BM blast count refers to myeloblasts or monoblasts.
.2. Treatment
Azacitidine was administered subcutaneously at the approved schedule of
5 mg/m2/day during 7 days every 28 days. Physicians intended to give at least
 cycles of treatment. Patients who responded well were to continue treatment
ntil progression. Red blood cell (RBC) transfusions were given in agreement with
eneral recommendations: Hb <8 g/dL. RBC transfusion dependency was deﬁned as
eceiving ≥2 RBC transfusions every 8 weeks.
.3. Response criteria and study endpoints
Response was  evaluated after every cycle by blood count and by bone marrow
spirate if available. All patients had received a bone marrow aspirate at diagnosis.
orphologic complete remission (CR), CR with incomplete blood count recovery
CRi), and partial remission (PR) were deﬁned according to IWG-2003 criteria for
ML [20]. Hematological improvement of the erythroid, neutrophil, and platelet
ineages was deﬁned by IWG-2006 criteria [21]. Overall survival (OS) was  deﬁned
s  the time from onset of azacitidine treatment to death. Patients who remained
live were censored at the last visit to the hospital.
.4. Statistical analysis
Analyses were made on an intent-to-treat basis. Differences between groups in
atient characteristics and response rates were compared using 2-sided Fisher’s
xact tests or chi-square tests for categorical variables and Student’s t-tests
r Mann–Whitney U tests for quantitative variables. Survival curves were esti-
ated with the Kaplan–Meier method. Predictive factors for OS were analyzed by
ald tests for univariate and multivariate comparisons. Cox proportional hazards
able 1
aseline patient characteristics by BM blast count; results are reported as N (%) or medi
yelodysplastic syndrome; WBC, white blood cell count; LDH, lacate dehydrogenase; WH
ith  a high leukocyte count of 146 × 109/L including 70 × 109/L peripheral blasts at basel
All patients (N = 55) <30% BM
Age (years) 
Median (range) 73 (59–84) 72 (60–8
Sex  
Female 14 (25%) 10 (26
AML,  type 
De  novo 34 (62%) 25 (66
Previous MDS 11 (20%) 6 (16
Therapy related 10 (18%) 7 (18
Cytogenetic risk 
Favorable 4 (4%) 2 (6
Intermediate 33 (64%) 21 (60
Poor  17 (33%) 12 (34
BM  blasts (%) 
Median (range) 25 (14–85) 22 (14–2
Circulating blasts 
Absent 19 (35%) 15 (39
Present 36 (65%) 23 (61
WBC  (×109/L)
Median (range) 3 (0–146§) 3 (0–1
≥15  × 109/L 12 (22%) 8 (21
LDH  
Increased 26 (51%) 18 (51
Transfusion dependency 
Present 33 (61%) 24 (63
WHO  performance score 
0–1  41 (79%) 29 (81
2–4  11 (21%) 7 (19Research 37 (2013) 877– 882
regression models were used to estimate hazard ratios and associated 95% conﬁ-
dence intervals (CI). A P-value < 0.05 was considered signiﬁcant. SPSS-19 was used
for  analysis.
3. Results
3.1. Baseline characteristics of the study population
The study population included 55 newly diagnosed and previ-
ously untreated AML  patients from 12 different hospitals. Baseline
characteristics are depicted in Table 1. Median age was  73 years
(range 59–84). The median BM blast count was 25% (14–85%); 38
(69%) patients had <30% BM blasts and 17 (31%) patients had ≥30%
BM blasts. There were no signiﬁcant differences in baseline charac-
teristics between patients with <30% and ≥30% BM blasts (Table 1).
3.2. Response to treatment and overall survival
The median number of azacitidine cycles was 6 (range 1–27)
(Table 2). Response was achieved in 23 (42%) patients, including
13 (24%) CR, 4 (7%) CRi, and 6 (11%) PR. Hematological improve-
ment was  achieved in 23 (42%) patients, of whom 15 patients had
improvement of the erythroid lineage, 19 of the platelet lineage,
and 7 of the neutrophil lineage, with combined responses of two  or
three lineages in 16 patients. Three patients had peripheral blood
counts that were too high at baseline to evaluate the hematolog-
ical improvement. Four patients had hematological improvement,
but achieved no CR or PR. Median time to response was  4 months
(range 1–10) and median time to hematological improvement was
2 months (range 1–7). Duration of response ranged from 9 to at least
27 months. Median duration of response was  not reached; response
was ongoing in 14 patients at the end of study. Transfusion depend-
ency was  present in 33 (61%) patients at baseline and 14 patients
became transfusion dependent during the ﬁrst two cycles. After 1
to 6 cycles, 14/47 (30%) patients became transfusion independent.
Failure to complete at least 3 cycles of azacitidine was  reported
in 16 (29%) patients. The reasons for discontinuation were disease
an (range). Abbreviations: BM,  bone marrow; AML, acute myeloid leukemia; MDS,
O, world health organization. § One patient with 27% BM blasts had myeloﬁbrosis
ine.
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Table  2
Treatment outcome by BM blast count; results are reported as N (%) or median (range). Abbreviations: BM,  bone marrow; CR, complete remission; CRi, CR with incomplete
blood  count recovery; PR, partial remission; HI, hematological improvement; CI, conﬁcence interval; NR, not reached.
All patients (N = 55) <30% BM blasts (N = 38) ≥30% BM blasts (N = 17) P
Number of azacitidine cycles 6 (1–27) 6 (1–27) 5 (1–24) 0.96
<3  cycles 14 (26%) 10 (26%) 4 (24%) 0.83
Response,  overall 23 (42%) 16 (42%) 7 (41%) 1.00
CR  13 (24%) 10 (26%) 3 (18%) 0.81
CRi  4 (7%) 2 (5%) 2 (12%)
PR  6 (11%) 4 (11%) 2 (12%)















































intermediate-risk group versus 4.1 months in the high-risk group
(P = 0.013) (Supplementary Fig. 2). In our cohort, the risk score pre-
dicted OS in patients with 20–30% BM blasts, as was shown beforeTime  to response (months) 4 (1–10)
Time  to HI (months) 2 (1–7) 
Overall survival (months) (95% CI) 12.3 (7.8–18.0) 
rogression and/or early death (N = 12), side-effects (pancytopenia
nd fever; N = 2), and consent withdrawal (N = 2). Dose adjustments
r schedule changes were made in 15 (27%) patients, of which 11
efore the sixth treatment cycle. Schedule change from 7 to 5 days
as applied in 9 patients; dose reductions of 50% were applied in
 patients, and 2 patients had dose reductions of 33% and 25%.
No differences in response rates (CR, CRi, PR) or hematologic
mprovement rates were found in patients with <30% versus ≥30%
M blasts (Table 2). Median OS of all patients was  12.3 months
95% CI 7.8–18.0 months). Patients with ≥30% BM blasts did not
ave a survival disadvantage (Table 2). Responders had a longer OS
han non-responders (median OS 24.3 versus 4.5 months, P < 0.001;
ig. 1A). Since it generally takes several cycles to achieve a response,
e compared also the patients who completed at least three cycles
f azacitidine. This analysis also demonstrated a longer median
S in responders compared to non-responders (24.3 versus 9.7
onths, P < 0.001; Supplementary Fig. 1). The OS in responders
nd non-responders was independent of the BM blast percentage
P = 0.33 and P = 0.47, respectively; Fig. 1B).
Interestingly, of the 17 patients with poor-risk cytogenetics, four
chieved a response (3 CR, 1 PR), which was associated with an
mproved OS compared to non-responding poor-risk patients (14.3
ersus 3.7 months; P = 0.01), illustrating the efﬁcacy of azacitidine
lso in patients with poor risk cytogenetics.
.3. Predictors for overall survival
We  analyzed potential predictors for OS that were selected
ased on previous studies [2,22]. Univariate analysis revealed no
ifference in OS in patients with <30% versus ≥30% BM blasts
Table 3a; Fig. 2A). In contrast, in univariate analysis, poor OS was
ssociated with poor-risk cytogenetics, therapy-related AML, and
HO  performance score ≥2 (Table 3a; Fig. 2B–D). Based on our pre-
ious experience, we were also interested in the predictive value of
latelet doubling after the ﬁrst cycle of azacitidine [17]. However,
nly 4 patients showed a platelet doubling after the ﬁrst cycle of
zacitidine. Therefore, platelet doubling was not included in further
nalyses.
For multivariate analysis, we selected predictors for OS with
 < 0.15 in univariate analysis. Multivariate analysis conﬁrmed
oor-risk cytogenetics, therapy-related AML, baseline WHO  per-
ormance score ≥2, and baseline WBC  ≥15 × 109/L as independent
dverse predictors for OS (Table 3b, Fig. 2E).
In addition, we assessed in our cohort of AML  patients the
zacitidine-speciﬁc prognostic scoring system that was  designed
nd validated for higher-risk MDS  patients and AML  patients with
0–30% BM blasts [17,22]. The azacitidine-speciﬁc prognostic score
as determined as follows: one point was assigned to performance
core ≥2, presence of circulating blasts, RBC transfusion depend-
ncy of ≥4 units/8 weeks, and intermediate-risk cytogenetics; and
wo points were assigned to poor-risk cytogenetics. The score could (2–10) 4 (1–6) 0.28
2 (1–4) 2 (1–7) 0.63
4.3 (7.8–20.6) 11.7 (1.5-NR) 0.55
be determined in 47 patients who  could subsequently be divided
into low- (score 0; N = 0), intermediate- (score 1–3; N = 37), and high
(score 4–5; N = 10) risk groups. Median OS was 12.7 months in theFig. 1. Patient survival by response to azacitidine. (A) Median OS was signiﬁ-
cantly better in responders compared to non-responders (24.3 versus 4.5 months;
P  < 0.001). (B) The BM blasts percentage had no impact on OS in responders (R) or
non-responders (NR).
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oig. 2. Impact of risk factors on survival of all patients. (A) BM blasts <30% versus ≥
ML  (t-AML). (D) WHO  performance score 0–1 versus 2–4. (E) WBC  <15 versus ≥15
17,23], and also signiﬁcantly predicted OS in the subgroup with
30% BM blasts (P = 0.006).
. Discussion
In this multicenter retrospective analysis, 55 patients with
ewly diagnosed and untreated AML  received azacitidine for
 median of 6 cycles. In 42% of the patients a response was
chieved, including 24% CR. These response rates are compara-
le with the results of the AML  patients in the AZA-001 trial
18% CR), with the previously untreated AML  patients enrolled
n an Italian compassionate program (overall response 50%), and
ith the previously untreated AML  patients included in a Ger-
an  prospective multicenter trial (overall response 48%) [14–16].
urther, in our study the median OS was 12.3 months, which
as less than the 24.5 months in the AZA-001 trial, but supe-
ior compared to the 9 months observed in the untreated patients
n the Italian NPP and 7.7 months in the German trial [14–16].
ltogether, these data show that the efﬁcacy of azacitidine in
ewly diagnosed AML  patients can also be conﬁrmed by the
xtended Dutch NPP. Interestingly, also patients with poor-risk
ytogenetics may  beneﬁt from azacitidine treatment. Indeed, in
ur study, 4 of 17 patients with poor-risk cytogenetics showed a) Cytogenetic risk score. (C) AML  de novo versus prior MDS  versus therapy-related
/L.
response to azacitidine which was  associated with an improved
OS.
Although azacitidine is currently only registered for the treat-
ment of AML  with 20–30% BM blasts, no differences in survival
and response rates were observed in patients with <30% and ≥30%
BM blasts. The ongoing AML-001 trial, which compares azaci-
tidine with intensive chemotherapy or best supportive care in
AML  patients with ≥30% blasts, should be awaited to conﬁrm our
observations in a prospective randomized clinical trial. The earlier
mentioned German and Italian studies did not compare the efﬁcacy
of azacitidine based on the percentage of BM blasts [15,16]. Fac-
tors that, in contrast to the percentage of BM blasts, signiﬁcantly
and independently predicted for OS were cytogenetic risk status,
AML  type (therapy-related), baseline WBC, and WHO  performance
score.
Identiﬁcation of patients who  are likely or unlikely to bene-
ﬁt from azacitidine treatment is, besides from a scientiﬁc- and
patient perspective, also an important issue in managing the costs
of healthcare. Therefore, it would be of help to have response pre-
dictors. In the French NPP, in a cohort of 282 higher-risk MDS
patients, four routine factors have been identiﬁed that were pre-
dictive for OS. The prognostic relevance of these factors (WHO
performance score, circulating blasts, RBC transfusion dependency,
L.H. van der Helm et al. / Leukemia 
Table  3
Predictors for overall survival: univariate and multivariate analysis. Abbreviations:
OS,  overall survival; HR, hazard ratio; CI, conﬁdence interval; AML, acute myeloid
leukemia; WBC, white blood cell count; LDH, lacate dehydrogenase; ref., reference
group; NR, not reached.*Signiﬁcant difference.
Median OS (months) HR (95% CI) P
(a) Univariate analysis
Bone marrow blasts 0.55
<30% 14.3 ref.
≥30% 11.7 1.3 (0.59–2.7)
Cytogenetic risk <0.008*
Favorable NR 1.1 (0.1–8.8) 0.91
Intermediate 10.2 ref.
Poor 2.6 3.1 (1.5–6.8) 0.003*
AML, type 0.086
De  novo 14.3 ref.
Previous MDS 12.7 1.0 (0.38–2.8) 0.96
Therapy related 3.2 2.5 (1.1–5.9) 0.038*
WHO  performance score 0.006*
0–1  12.7 ref.
≥2 3.2 3.0 (1.4–6.5)
WBC  0.11
<15  × 109/L 14.3 ref.
≥15 × 109/L 6.0 1.9 (0.86–4.2)
LDH 0.34
Normal 12.3 ref.
Increased 11.5 1.4 (0.69–2.9)
Circulating blasts 0.44
Absent 15.0 ref.
Present 11.5 1.4 (0.6–2.9)
Transfusion dependency 0.17
No  18.0 ref.
Yes 11.5 1.7 (0.80–3.8)
(b)  Multivariate analysis
Cytogenetic risk 0.001*
Favorable NR 0.12 (0.01–1.2) 0.073
Intermediate 10.2 ref.
Poor 2.6 3.9 (1.6–9.3) 0.002*
AML, type 0.002*
De novo 14.3 ref.
Previous MDS  12.7 2.1 (0.68–6.8) 0.19
Therapy related 3.2 8.9 (2.7–29.3) <0.001*
WHO  performance score <0.001*
0–1  12.7 ref.
≥2 3.2 7.3 (2.6–20.0)


























[<15 × 109/L 14.3 ref.
≥15 × 109/L 6.0 5.3 (1.7–15.8)
nd cytogenetic risk) could be conﬁrmed in our cohort of 55
ntreated AML  patients and might be of beneﬁt for the design of
uture trials.
Finally, the treatment of older AML  patients is clinically chal-
enging. Our data on 55 newly diagnosed and previously untreated
ML patients suggest that administration of azacitidine to older
ML patients is feasible and also has a favorable impact on outcome
n patients with more than 30% BM blasts.
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